bpc 157 leaky gut: Frequently asked questions

Oral bioavailability remains debated. Gastric acid and digestive enzymes degrade peptide bonds, theoretically reducing intact absorption. Yet anecdotal reports and limited studies suggest local gut repair may occur even if systemic absorption is low, as the peptide contacts damaged tissue directly during transit. Oral dosing typically requires 2–3× higher doses (500–750 mcg daily) to account for degradation losses. Subcutaneous injection bypasses this entirely, delivering the full dose systemically and allowing circulation to damaged gut tissue via bloodstream. For leaky gut specifically, injectable routes show more consistent timelines in user reports.

Transient symptom aggravation during early BPC-157 use is common and typically reflects increased immune activity as damaged tissue begins turnover. The gut barrier is undergoing cellular regeneration, which temporarily elevates inflammatory signaling before improvement manifests. Reduce dose by 50% (from 500 mcg to 250 mcg daily) and extend the titration period. Slower escalation allows adaptation without overwhelming already-stressed systems. If bloating, cramping, or loose stools persist beyond week two, evaluate for concurrent SIBO or dysbiosis; BPC-157 repairs structure but doesn't address bacterial overgrowth, which requires separate antimicrobial intervention.

Continue the protocol through week eight before reassessing. Cellular repair precedes symptom relief, and individual timelines vary based on baseline gut permeability severity, concurrent medications (NSAIDs, PPIs), and dietary adherence. If you're still consuming high-inflammatory foods (gluten, processed seed oils, excess alcohol), the peptide is repairing damage while you're actively re-injuring tissue. Net progress stalls. Labs can confirm progress even when symptoms lag: request a zonulin test (serum marker of intestinal permeability) or lactulose-mannitol test at week four and week eight to track objective barrier improvement independent of subjective feelings.

Reassess whether intestinal hyperpermeability is the actual limiting factor in your symptoms. Leaky gut is a mechanism. Not a diagnosis. And systemic inflammation, brain fog, or digestive distress can stem from SIBO, histamine intolerance, bile acid malabsorption, or microbiome dysbiosis without barrier dysfunction. Consider lactulose-mannitol testing or serum zonulin measurement to confirm permeability before attributing lack of response to peptide inefficacy. If confirmed leaky gut persists despite BPC-157, the underlying driver (chronic NSAID use, gluten exposure, alcohol, pathogenic bacteria) may still be active.

Yes. BPC-157's mechanism (tight junction upregulation and growth factor modulation) is complementary to glutamine's metabolic support and zinc carnosine's mucosal protection. There are no documented negative interactions between these agents in published literature. Combining BPC-157 with butyrate or collagen peptides may provide additive benefit by addressing both structural repair (BPC-157) and fuel/substrate availability (butyrate, collagen). Our experience working with researchers in this space suggests layered protocols often outperform single-agent approaches when the goal is comprehensive barrier restoration.

Discard it immediately. Cloudiness, yellow discolouration, or visible particulates indicate contamination, degradation, or improper lyophilisation. Properly reconstituted BPC-157 should be clear and colourless. Temperature excursions during shipping or storage denature the peptide structure, rendering it biologically inactive. At Real Peptides, every batch undergoes sterile filtration and is shipped with cold packs to maintain the required −20°C to 2–8°C range throughout transit.

First suspect peptide degradation from improper storage or reconstitution. Temperature excursions above 8°C denature the protein irreversibly. A vial that sat at room temperature during shipping is useless even if it looks normal. Second, confirm that bacterial overgrowth or parasitic infection isn't driving permeability faster than the peptide can repair it. BPC-157 stabilizes junctions, but active gut infections create permeability through toxin production that overwhelms repair capacity.

No, unless root causes are addressed concurrently. Tight junction stability depends on sustained FAK signaling, which stops when peptide administration stops. A 2018 study tracked post-withdrawal permeability and found regression to baseline within 18 days. Use the peptide window to implement microbiome rebalancing, eliminate barrier irritants, and restore mucosal immunity. BPC-157 buys time, it doesn't solve the underlying dysfunction.

Barrier restoration will occur during peptide administration, but permeability will return within 10–21 days of stopping if dietary irritants (alcohol, NSAIDs, high-FODMAP foods, gluten in susceptible individuals) continue unchecked. BPC-157 provides a stabilization window. Not permanent correction. The peptide anchors tight junctions mechanically, but ongoing inflammation from unresolved triggers destabilizes those junctions once FAK signaling stops.